Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Bevacizumab treatment for solid tumors: boon or bust?

Hayes DF.

JAMA. 2011 Feb 2;305(5):506-8. doi: 10.1001/jama.2011.57. No abstract available.

PMID:
21285431
2.

Maximizing the potential of bevacizumab in cancer treatment.

Bergsland E, Dickler MN.

Oncologist. 2004;9 Suppl 1:36-42. Review.

3.

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

Ranpura V, Hapani S, Wu S.

JAMA. 2011 Feb 2;305(5):487-94. doi: 10.1001/jama.2011.51. Review. Erratum in: JAMA. 2011 Jun 8;305(22):2294.

PMID:
21285426
4.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
5.

Angiogenesis inhibition in the treatment of lung cancer.

Vokes E, Herbst R, Sandler A.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2. Review.

PMID:
17143257
6.

Bevacizumab: current updates in treatment.

Van Meter ME, Kim ES.

Curr Opin Oncol. 2010 Nov;22(6):586-91. doi: 10.1097/CCO.0b013e32833edc0c. Review.

PMID:
20811277
7.

Anti-angiogenic therapies for metastatic colorectal cancer.

Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005392. doi: 10.1002/14651858.CD005392.pub3. Review.

PMID:
19588372
8.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

9.

Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

Schmucker C, Antes G, Lelgemann M.

Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002. Review. No abstract available.

PMID:
19818262
10.

[Treatment with antiangiogenic drugs].

Saijo N.

Nihon Rinsho. 2010 Jun;68(6):1007-13. Review. Japanese.

PMID:
20535948
11.
12.

Managing patients with metastatic colorectal cancer on bevacizumab.

Lemmens L, Claes V, Uzzell M.

Br J Nurs. 2008 Aug 14-Sep 10;17(15):944-9. Review.

PMID:
18983014
13.

Bevacizumab in the treatment of ovarian cancer.

Han ES, Monk BJ.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1339-45. Review.

PMID:
17944559
14.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D.

Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.

PMID:
20063120
15.

Bevacizumab in the treatment of metastatic breast cancer.

Traina TA.

Oncology (Williston Park). 2009 Apr 15;23(4):327-32. Review.

16.
17.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
18.

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.

Krämer I, Lipp HP.

J Clin Pharm Ther. 2007 Feb;32(1):1-14. Review.

PMID:
17286784
19.

Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.

Chamberlain MC.

Cancer. 2010 Sep 1;116(17):3988-99. doi: 10.1002/cncr.25256. Review.

20.

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S.

JAMA. 2008 Nov 19;300(19):2277-85. doi: 10.1001/jama.2008.656. Review.

PMID:
19017914

Supplemental Content

Support Center